Two Immunoscore clinical studies in stage III colon cancer patients validated the clinical value of Immunoscore to refine patients stratification and predict which patients benefit most from 6 months adjuvant chemotherapy.
Immunoscore is sponsored by HalioDx SAS.
Published in JNCI Cancer Spectrum, the Immunoscore-N0147 study was conducted in collaboration with clinicians and researchers from the Mayo Clinic. The Immunoscore-IDEA France study, published in Annals of Oncology, was conducted in collaboration with PRODIGE, a digestive oncology intergroup gathering the GERCOR, the FFCD and UNICANCER organizations. Objectives of these retrospective studies in prospectively conducted trials were to examine and validate the ability of Immunoscore to identify patients at high-risk of relapse and investigate survival differences according to Immunoscore in predefined subgroups, including Tumor/Node Stage and treatment duration.
The two studies were performed on independent large phase III randomized clinical trials cohorts, and included 559 patient samples from the FOLFOX alone arm of the NCCTG N0147 trial3, and 1062 patient samples from both arms (3 versus 6 months) of the IDEA France trial4 (as part of the IDEA international collaboration5). Consistent prognostic performances were obtained, and Immunoscore predictive performance was demonstrated for FOLFOX therapy duration.
